Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Quotient Sciences Ltd.. (11/14/17). "Press Release: Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization". Nottingham.

Organisations Organisation Quotient Sciences Ltd.
  Group Quotient (Group)
  Organisation 2 Pharmaterials Ltd.
  Group Quotient (Group)
Products Product contract research (drugs)
  Product 2 drug development services
Index term Index term Pharmaceuticals International–Quotient: investment, 201711 acquisition of Pharmaterials Ltd by Quotient Sciences Ltd
Persons Person Egerton, Mark (Quotient Bioresearch 201010)
  Person 2 Bodicoat, Robin (Quotient 201711 Marketing Director at Quotient Sciences)

Quotient Sciences (“Quotient”), the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the U.K., and further supports the growth of Quotient’s Translational Pharmaceutics® platform, following the acquisitions of SeaView Research and QS Pharma in February 2017.

Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The company’s portfolio of services spans the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply. The business was founded in 2000 and is located in a 48,000-square feet facility that houses 13 GMP manufacturing suites, with space for future expansion.

Mark Egerton, CEO, Quotient Sciences, said: “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”

With over 700 employees, six operating sites across the U.S. and U.K. and a 30-year track record for quality services, Quotient is focused on delivering an innovative portfolio of services that are proven to shorten development timelines, reduce associated costs and accelerate the delivery of new medicines to patients globally.


For further information, please contact:

Zyme Communications
Katie Odgaard
Tel: +44 (0)7787 502 947

Quotient Sciences
Robin Bodicoat
Marketing Director
Tel: +44 (0)115 931 5102

About Quotient Sciences

Quotient Sciences, a global pharmaceutical development, clinical pharmacology, and clinical and commercial manufacturing organization, delivers innovative, customized solutions for pharmaceutical and biotech customers through both individual and integrated services. Its Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research for the continuous improvement of drug development programs, and is proven to accelerate timelines and reduce cost.

For more information, visit

About Pharmaterials

Pharmaterials Ltd. is a contract development and manufacturing organization, specializing in the drug substance screening, formulation development and manufacturing of preclinical & early phase oral and inhaled dosage forms.

For more information, visit

Record changed: 2017-11-26


Picture [LSA] – The Business Web Portal 650x89px

More documents for Quotient (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top